MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
0.9600
-0.0318
-3.21%
After Hours: 1.040 +0.08 +8.33% 16:14 03/21 EDT
OPEN
1.010
PREV CLOSE
0.9918
HIGH
1.030
LOW
0.9495
VOLUME
201.93K
TURNOVER
--
52 WEEK HIGH
1.690
52 WEEK LOW
0.7736
MARKET CAP
34.10M
P/E (TTM)
-1.6783
1D
5D
1M
3M
1Y
5Y
1D
RENOVORX CEO TO PROVIDE STRATEGIC UPDATE DURING FIRESIDE CHAT ON THURSDAY, APRIL 3RD AT 12:00 P.M. ET
Reuters · 2d ago
Weekly Report: what happened at RNXT last week (0310-0314)?
Weekly Report · 5d ago
Weekly Report: what happened at RNXT last week (0303-0307)?
Weekly Report · 03/10 11:12
Weekly Report: what happened at RNXT last week (0224-0228)?
Weekly Report · 03/03 11:11
RenovoRx advnaces RenovoCath commercialization
TipRanks · 02/26 13:21
Weekly Report: what happened at RNXT last week (0217-0221)?
Weekly Report · 02/24 11:11
Weekly Report: what happened at RNXT last week (0210-0214)?
Weekly Report · 02/17 11:08
RenovoRx presents data from Trans-Arterial Micro-Perfusion therapy platform
TipRanks · 02/13 13:27
More
About RNXT
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.